Int J Stomatol

Inter J Stomatol ›› 2018, Vol. 45 ›› Issue (2): 135-139.doi: 10.7518/gjkq.2018.02.003

• Oral Medicine • Previous Articles     Next Articles

Clinical significance of CD20 expression in oral potentially malignant disorders

Liu Yi1,2, Zhou Hao1, Fei Wei1   

  1. 1.Dept. of Stomatology, Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital, Affiliated Hospital to University of Electronic Science and Technology of China, Chengdu 610072, China
    2.College of Oral Biological and Medical Sciences, Faculty of Dentistry, University of British Columbia, Vancouver BC V6T 1Z3, Canada
  • Received:2017-09-29 Revised:2017-12-03 Online:2018-03-01 Published:2018-03-01
  • Supported by:
    This study was supported by National Natural Science Foundations of China (81502362).

RichHTML

10

PDF (PC)

196

Abstract: Objective This study aims to investigate the expression of C20 in oral potentially malignant disorders (OPMDs) by using the histological analysis and evaluates the clinical value of using CD20 as indices to assess the carcinogenic potential of OPMDs.Methods Clinical data from 17 cases with oral hyperplasia mucosa, 21 cases with oral lichen planus (OLP), 15 cases with mild oral dysplasia mucosa (D1), and 9 cases with mild moderate dysplasia mucosa (D2) were analyzed by using retrospective analysis. Immunohistochemical analysis was applied to investigate the expression of CD20 in paraffin sections of oral hyperplasia mucosa, OLP, D1, and D2 tissues. Subsequently, the relationships between such expression and clinical factors were investigated.Results Results The positive rates of CD20 expression in the oral hyperplasia mucosa, OLP, D1, and D2 mucosa were 11.76%, 61.90%, 20.00%, and 66.67% (P<0.05), respectively. CD20 expression was found uncorrelated with age, gender, region, alcohol use, and smoking status (P>0.05). The multiple-factor analysis showed that the odds ratios of OLP and D2 significantly increased (P<0.05) when oral hyperplasia mucosa was used as the reference group. Conclusion CD20 may be used individually as clinical index to evaluate the carcinogenic potential of OPMDs.

Key words: CD20, B cell, oral potentially malignant disorders

CLC Number: 

  • R781.5

TrendMD: 
[1] Warnakulasuriya S, Johnson NW, van der Waal I. No-menclature and classification of potentially malignant disorders of the oral mucosa[J]. J Oral Pathol Med, 2007, 36(10):575-580.
[2] Rhodus NL. Oral cancer and precancer: improving outcomes[J]. Compend Contin Educ Dent, 2009, 30 (8):486-488, 490-494, 496-498, 504, 520.
[3] 高岩. WHO口腔黏膜癌前病变组织学新分类及其进展[J]. 中国实用口腔科杂志, 2008, 1(12):705-708.
Gao Y.WHO new classification and progress of the histology of the precancerous lesion of oral mucosa[J]. Chin J Pract Stomatol, 2008, 1(12):705-708.
[4] Warnakulasuriya S, Reibel J, Bouquot J, et al.Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement[J]. J Oral Pathol Med, 2008, 37(3):127-133.
[5] Johnson NW, Warnakulasuriya S, Gupta PC, et al.Global oral health inequalities in incidence and out-comes for oral cancer: causes and solutions[J]. Adv Dent Res, 2011,23(2):237-246.
[6] 石佳鸿, 周红梅. 口腔潜在恶性病变的无创筛查及管理[J]. 中国实用口腔科杂志, 2015, 8(12):705-708.
Shi JH, Zhou HM.Noninvasive screening and inter-vention of oral potential malignant disorders[J]. Chin J Pract Stomatol, 2015, 8(12):705-708.
[7] Thompson L.World Health Organization classification of tumours: pathology and genetics of head and neck tumours[J]. Ear Nose Throat J, 2006, 85(2):74.
[8] Sun L, Feng J, Ma L, et al.CD133 expression in oral lichen planus correlated with the risk for progression to oral squamous cell carcinoma[J]. Ann Diagn Pathol, 2013, 17(6):486-489.
[9] Edwards PC, Kelsch R.Oral lichen planus: clinical presentation and management[J]. J Can Dent Assoc, 2002, 68(8):494-499.
[10] Sousa FA, Paradella TC, Brandão AA, et al.Oral lichen planus versus epithelial dysplasia: difficulties in diagnosis[J]. Braz J Otorhinolaryngol, 2009, 75(5):716-720.
[11] 林文棠, 朱平. 实用临床免疫学[M]. 西安: 第四军医大学出版社, 2003:468.
Lin WT, Zhu P.Applied clinical immunology[M]. Xi’an: The Fourth Military Medical University Press, 2003:468.
[12] 郑智, 方泽民, 潘友民, 等. B细胞与肿瘤免疫的研究进展[J]. 现代肿瘤医学, 2012, 20(12):2652-2654.
Zheng Z, Fang ZM, Pan YM, et al.Advances in the research of B lymphocyte and tumor immunity[J]. Modern Oncol, 2012, 20(12):2652-2654.
[1] Lin Huiping,Xu Ting,Lin Jun.. Research progress on artificial intelligence techniques in diagnosis of oral cancer and potentially malignant disorders [J]. Int J Stomatol, 2023, 50(2): 138-145.
[2] He Yuqing,Dan Hongxia,Chen Qianming. Application of photodynamic therapy for oral carcinogenesis prevention [J]. Int J Stomatol, 2020, 47(6): 669-676.
[3] WEN Hai-yan, SHU Rong. Research advance of Nifedipine induced gingival hyperplasia [J]. Inter J Stomatol, 2009, 36(1): 84-84～87.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[2] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[3] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[4] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[5] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[6] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[7] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[8] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[9] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[10] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .